The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system

D. Clapp, D. A. Williams

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human umbilical cord blood contains abundant primitive and committed hematopoietic progenitors and has been used as an alternative source of reconstituting hematopoietic stem cells. Recent advances in the understanding of molecular aspects of multiple diseases and improvements in technology associated with prenatal diagnosis now allow the in utero identification of many genetic diseases affecting the hematopoietic system. Advances in technology raise the potential for genetic correction and subsequent transplantation of autologous cord and placental blood hematopoietic stem cells into affected patients prior to expression of the disease phenotype. This review will summarize the recent data on advances in prenatal diagnosis, characterization of the biology of cord blood stem cells, and efforts at developing methods for genetic transduction of cord blood hematopoietic stem/progenitor cells.

Original languageEnglish
Pages (from-to)613-621
Number of pages9
JournalStem Cells
Volume13
Issue number6
StatePublished - 1995

Fingerprint

Hematopoietic System
Inborn Genetic Diseases
Hematopoietic Stem Cells
Fetal Blood
Prenatal Diagnosis
Genetic Transduction
Technology
Autologous Transplantation
Blood Cells
Stem Cells
Phenotype

Keywords

  • Cord blood
  • Gene therapy
  • Gene transfer
  • Hematopoiesis
  • Ontogeny
  • Retroviral vectors

ASJC Scopus subject areas

  • Cell Biology

Cite this

The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system. / Clapp, D.; Williams, D. A.

In: Stem Cells, Vol. 13, No. 6, 1995, p. 613-621.

Research output: Contribution to journalArticle

@article{1f0fdae4762d4630b9bf1f6ae306f37a,
title = "The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system",
abstract = "Human umbilical cord blood contains abundant primitive and committed hematopoietic progenitors and has been used as an alternative source of reconstituting hematopoietic stem cells. Recent advances in the understanding of molecular aspects of multiple diseases and improvements in technology associated with prenatal diagnosis now allow the in utero identification of many genetic diseases affecting the hematopoietic system. Advances in technology raise the potential for genetic correction and subsequent transplantation of autologous cord and placental blood hematopoietic stem cells into affected patients prior to expression of the disease phenotype. This review will summarize the recent data on advances in prenatal diagnosis, characterization of the biology of cord blood stem cells, and efforts at developing methods for genetic transduction of cord blood hematopoietic stem/progenitor cells.",
keywords = "Cord blood, Gene therapy, Gene transfer, Hematopoiesis, Ontogeny, Retroviral vectors",
author = "D. Clapp and Williams, {D. A.}",
year = "1995",
language = "English",
volume = "13",
pages = "613--621",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system

AU - Clapp, D.

AU - Williams, D. A.

PY - 1995

Y1 - 1995

N2 - Human umbilical cord blood contains abundant primitive and committed hematopoietic progenitors and has been used as an alternative source of reconstituting hematopoietic stem cells. Recent advances in the understanding of molecular aspects of multiple diseases and improvements in technology associated with prenatal diagnosis now allow the in utero identification of many genetic diseases affecting the hematopoietic system. Advances in technology raise the potential for genetic correction and subsequent transplantation of autologous cord and placental blood hematopoietic stem cells into affected patients prior to expression of the disease phenotype. This review will summarize the recent data on advances in prenatal diagnosis, characterization of the biology of cord blood stem cells, and efforts at developing methods for genetic transduction of cord blood hematopoietic stem/progenitor cells.

AB - Human umbilical cord blood contains abundant primitive and committed hematopoietic progenitors and has been used as an alternative source of reconstituting hematopoietic stem cells. Recent advances in the understanding of molecular aspects of multiple diseases and improvements in technology associated with prenatal diagnosis now allow the in utero identification of many genetic diseases affecting the hematopoietic system. Advances in technology raise the potential for genetic correction and subsequent transplantation of autologous cord and placental blood hematopoietic stem cells into affected patients prior to expression of the disease phenotype. This review will summarize the recent data on advances in prenatal diagnosis, characterization of the biology of cord blood stem cells, and efforts at developing methods for genetic transduction of cord blood hematopoietic stem/progenitor cells.

KW - Cord blood

KW - Gene therapy

KW - Gene transfer

KW - Hematopoiesis

KW - Ontogeny

KW - Retroviral vectors

UR - http://www.scopus.com/inward/record.url?scp=0028787058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028787058&partnerID=8YFLogxK

M3 - Article

C2 - 8590863

AN - SCOPUS:0028787058

VL - 13

SP - 613

EP - 621

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -